DOCSLIB.ORG

HCC and Cancer Mutated Genes Summarized in the Literature Gene Symbol Gene Name References*

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HCC and Cancer Mutated Genes Summarized in the Literature Gene Symbol Gene Name References* HCC and cancer mutated genes summarized in the literature Gene symbol Gene name References* A2M Alpha-2-macroglobulin (4) ABL1 c-abl oncogene 1, receptor tyrosine kinase (4,5,22) ACBD7 Acyl-Coenzyme A binding domain containing 7 (23) ACTL6A Actin-like 6A (4,5) ACTL6B Actin-like 6B (4) ACVR1B Activin A receptor, type IB (21,22) ACVR2A Activin A receptor, type IIA (4,21) ADAM10 ADAM metallopeptidase domain 10 (5) ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 (4) ADCY2 Adenylate cyclase 2 (brain) (26) AJUBA Ajuba LIM protein (21) AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 (4) Akt AKT serine/threonine kinase (28) AKT1 v-akt murine thymoma viral oncogene homolog 1 (5,21,22) AKT2 v-akt murine thymoma viral oncogene homolog 2 (4) ALB Albumin (4) ALK Anaplastic lymphoma receptor tyrosine kinase (22) AMPH Amphiphysin (24) ANK3 Ankyrin 3, node of Ranvier (ankyrin G) (4) ANKRD12 Ankyrin repeat domain 12 (4) ANO1 Anoctamin 1, calcium activated chloride channel (4) APC Adenomatous polyposis coli (4,5,21,22,25,28) APOB Apolipoprotein B [including Ag(x) antigen] (4) AR Androgen receptor (5,21-23) ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 (4) ARHGAP35 Rho GTPase activating protein 35 (21) ARID1A AT rich interactive domain 1A (SWI-like) (4,5,21,22,24,25,27,28) ARID1B AT rich interactive domain 1B (SWI1-like) (4,5,22) ARID2 AT rich interactive domain 2 (ARID, RFX-like) (4,5,22,24,25,27,28) ARID4A AT rich interactive domain 4A (RBP1-like) (28) ARID5B AT rich interactive domain 5B (MRF1-like) (21) ASPM Asp (abnormal spindle) homolog, microcephaly associated (Drosophila) (4) ASXL1 Additional sex combs like 1 (Drosophila) (21,22) ATAD3B Similar to AAA-ATPase TOB3; ATPase family, AAA domain containing 3B (23) ATM Similar to serine-protein kinase ATM (Ataxia telangiectasia mutated) (A-T, mutated); ataxia telangiectasia mutated (4,5,21,22,25,27) ATP10A ATPase, class V, type 10A (4) ATP10B ATPase, class V, type 10B (4) ATP13A1 ATPase type 13A1 (4) ATR Ataxia telangiectasia and Rad3 related; similar to ataxia telangiectasia and Rad3 related protein (4,5,21) ATRX Alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae) (21,22) AXIN1 Axin 1 (1,2,3,5,6,7,9 AXIN2 Axin 2 (4,21) AXL AXL receptor tyrosine kinase (4) B2M Beta-2-microglobulin (22) B4GALT3 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 3 (21) BAF170 Also known as SMARCC2 (5) BAF53 Brahma associated protein 53 kDa (5) BAF60 Brahma associated protein 60 kDa (5) BAG3/4 BCL2 associated athanogene 3/4 (28) BAP1 BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase) (21,22) BCL2 B-cell CLL/lymphoma 2 (22) BCL9 B-cell CLL/lymphoma 9 (25) BCOR BCL6 co-repressor (22) BRAF v-raf murine sarcoma viral oncogene homolog B1 (4,21,22,25) BRCA1 Breast cancer 1, early onset (5,21,22) BRCA2 Breast cancer 2, early onset (21,22) BRD7 Bromodomain containing 7; bromodomain containing 7 pseudogene 2 (5) BRD9 Bromodomain containing 9 (23) C18orf34 Chromosome 18 open reading frame 34 (24) CACNA1F Calcium channel, voltage-dependent, L type, alpha 1F subunit (4) CACNA1H Calcium channel, voltage-dependent, T type, alpha 1H subunit (4) CACNA2D4 Calcium channel, voltage-dependent, alpha 2/delta subunit 4 (26) CACNG2 Calcium channel, voltage-dependent, gamma subunit 2 (5) CACNG4 Calcium channel, voltage-dependent, gamma subunit 4 (23) CALM1 Calmodulin 3 (phosphorylase kinase, delta); calmodulin 2 (phosphorylase kinase, delta); calmodulin 1 (phosphorylase kinase, delta) (5) CAMK2A Calcium/calmodulin-dependent protein kinase II alpha (5) CAMK2G Calcium/calmodulin-dependent protein kinase II gamma (5) CARD11 Caspase recruitment domain family, member 11 (22) CASP8 Caspase 8, apoptosis-related cysteine peptidase (22) CBFB Core-binding factor, beta subunit (21) CBL Cas-Br-M (murine) ecotropic retroviral transforming sequence (22) CCND1 Cyclin D1 (4,5,21,25) CCNE1 Cyclin E1 (4,5) CCT6B Chaperonin containing TCP1, subunit 6B (zeta 2) (28) CCT8L2 Chaperonin containing TCP1, subunit 8 (theta)-like 2 (28) CD109 CD109 molecule (4) CDC73 Cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. Cerevisiae) (22) CDH1 Cadherin 1, type 1, E-cadherin (epithelial) (21,22) CDH7 Cadherin 7, type 2 (4) CDK11A Similar to cell division cycle 2-like 1 (PITSLRE proteins); cell division cycle 2-like 1 (PITSLRE proteins); cell division cycle 2-like 2 (PITSLRE proteins) (28) CDK11B Similar to cell division cycle 2-like 1 (PITSLRE proteins); cell division cycle 2-like 1 (PITSLRE proteins); cell division cycle 2-like 2 (PITSLRE proteins) (28) CDK12 Cdc2-related kinase, arginine/serine-rich (21) CDK4 Cyclin-dependent kinase 4 (4) CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) (4,5,21) CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) (5,21,28) CDKN2A Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) (4,5,21,22,25,27,28) CDKN2B Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (4 CDKN2C Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) (21,28) CEBPA CCAAT/enhancer binding protein (C/EBP), alpha (21,22) CFH Complement factor H (4) CFHR1 Complement factor H-related 1 (4) CFHR2 Complement factor H-related 2 (4) CHD1L Chromodomain helicase DNA binding protein 1-like (25) CHD3 Chromodomain helicase DNA binding protein 3 (28) CHD4 Chromodomain helicase DNA binding protein 4 (28) CHD7 Chromodomain helicase DNA binding protein 7 (4) CHEK1 CHK1 checkpoint homolog (S. Pombe) (5) CHEK2 Protein kinase CHK2-like; CHK2 checkpoint homolog (S. Pombe); similar to hcg1983233 (5,21) CIC Capicua homolog (Drosophila) (22) CLTC Clathrin, heavy chain (Hc) (4) CNOT1 CCR4-NOT transcription complex, subunit 1 (4) COL11A1 Collagen, type XI, alpha 1 (26) COL12A1 Collagen, type XII, alpha 1 (4) COL16A1 Collagen, type XVI, alpha 1 (4) COL1A1 Collagen, type I, alpha 1 (25) COL1A2 Collagen, type I, alpha 2 (4) COL3A1 Collagen, type III, alpha 1 (4) COL5A1 Collagen, type V, alpha 1 (4) COL6A3 Collagen, type VI, alpha 3 (4) COL7A1 Collagen, type VII, alpha 1 (4) CPA2 Carboxypeptidase A2 (pancreatic) (23) CREBBP CREB binding protein (4,5,22) CRIPAK Cysteine-rich PAK1 inhibitor (21) CRLF2 Cytokine receptor-like factor 2 (22) CS Citrate synthase (4) CSF1R Colony stimulating factor 1 receptor (22) CSMD3 CUB and Sushi multiple domains 3 (24) CSNK1A1 Casein kinase 1, alpha 1 (5) CSNK1E Casein kinase 1, epsilon (28) CTCF CCCTC-binding factor (zinc finger protein) (21) CTNNB1 Catenin (cadherin-associated protein), beta 1, 88 kDa (4,5,21-23,25-28) CUL3 Cullin 3 (4,5) CYLD Cylindromatosis (turban tumor syndrome) (22) CYP11B2 Cytochrome P450, family 11, subfamily B, polypeptide 2 (4) CYP2E1 Cytochrome P450, family 2, subfamily E, polypeptide 1 (28) CYP2F1 Cytochrome P450, family 2, subfamily F, polypeptide 1 (28) DAPK1 Death-associated protein kinase 1 (4) DAXX Death-domain associated protein (22) DCHS1 Dachsous 1 (Drosophila) (4) DLC1 Deleted in liver cancer 1 (28) DLG1 Discs, large homolog 1 (Drosophila) (5) DLL1 Delta-like 1 (Drosophila) (5) DMD Dystrophin (4) DNAH12 Dynein, axonemal, heavy chain 12 (4) DNAH3 Dynein, axonemal, heavy chain 3 (4) DNAJB3 DnaJ (Hsp40) homolog, subfamily B, member 3 (28) DNAJC22 DnaJ (Hsp40) homolog, subfamily C, member 22 (28) DNMT1 DNA (cytosine-5-)-methyltransferase 1 (22) DNMT3A DNA (cytosine-5-)-methyltransferase 3 alpha (21,22) DOCK2 Dedicator of cytokinesis 2 (4) DSCAM Down syndrome cell adhesion molecule (4) DSE Dermatan sulfate epimerase (24) DSP Desmoplakin (4) DST Dystonin (4) DTX1 Deltex homolog 1 (Drosophila) (5) DVL1 Dishevelled, dsh homolog 1 (Drosophila); dishevelled, dsh homolog 1 (Drosophila)-like 1 (5) EDEM1 ER degradation enhancer, mannosidase alpha-like 1 (28) EGF Epidermal growth factor (beta-urogastrone) (5) EGFR Epidermal growth factor receptor [erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian] (4,5,21,22) EGR3 Early growth response 3 (21) EIF4A2 Similar to eukaryotic translation initiation factor 4A2; eukaryotic translation initiation factor 4A, isoform 2 (21) ELAVL1 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) (23) ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific) (21) ELMO1 Engulfment and cell motility 1 (24) EP300 E1A binding protein p300 (4,21,22,28) EPB41L3 Erythrocyte membrane protein band 4.1-like 3 (4) EPHA3 EPH receptor A3 (21) EPHA4 EPH receptor A4 (4) EPHB6 EPH receptor B6 (21) EPPK1 Epiplakin 1 (21) EPS15 Epidermal growth factor receptor pathway substrate 15 (26) ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (4,22) ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (5) ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) (5,21) ERCC2 Excision repair cross-complementing rodent repair deficiency, complementation group 2 (21) EREG Epiregulin (5 ERN1 Endoplasmic reticulum to nucleus signaling 1 (28) EZH2 Enhancer of zeste homolog 2 (Drosophila) (21,22) F10 Coagulation factor X (5) F2 Coagulation factor II (thrombin) (5) F2R Coagulation factor II (thrombin) receptor (5) F7 Coagulation factor VII (serum prothrombin conversion accelerator) (5) F8 Coagulation factor VIII, procoagulant component (4) FAM120C Family with sequence similarity 120C (4) FAM123B Family with sequence similarity 123B (22) FAM5C Family with sequence similarity 5, member C (26) FASN Fatty acid synthase (4) FAT4 FAT tumor suppressor homolog 4 (Drosophila) (4) FBN1 Fibrillin 1 (4) FBXW7 F-box and WD repeat domain containing
Load more

Recommended publications
  • Targeting Synthetic Lethality Between the SRC Kinase and the EPHB6 Receptor May Benefit Cancer Treatment
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 31 Research Paper Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment James M. Paul1,*, Behzad Toosi2,*, Frederick S. Vizeacoumar2,*, Kalpana Kalyanasundaram Bhanumathy2, Yue Li3,4,5, Courtney Gerger2, Amr El Zawily2,6, Tanya Freywald7, Deborah H. Anderson7, Darrell Mousseau8, Rani Kanthan2, Zhaolei Zhang3,4, Franco J. Vizeacoumar2,7, Andrew Freywald2 1Department of Biochemistry, University of Saskatchewan, Saskatoon, SK, S7N 5E5, Canada 2Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Royal University Hospital, Saskatoon, SK, S7N 0W8, Canada 3Department of Computer Science, University of Toronto, Toronto, ON, M5S 3G4, Canada 4The Donnelly Centre, University of Toronto, Toronto, ON, M5S 3E1, Canada 5Present address: Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA 6Faculty of Science, Damanhour University, Damanhour, 22516, Egypt 7Cancer Research, Saskatchewan Cancer Agency, Saskatoon, SK, S7N 5E5, Canada 8Cell Signaling Laboratory, Neuroscience Cluster, University of Saskatchewan, Saskatoon, SK, S7N 5E5, Canada *These authors contributed equally to this work Correspondence to: Franco J. Vizeacoumar, email: [email protected] Andrew Freywald, email: [email protected] Keywords: breast cancer, genetic interaction, synthetic lethality, EPHB6, SRC kinase Received: April 22, 2016 Accepted: June 17, 2016 Published: July 13, 2016 ABSTRACT Application of tumor genome sequencing has identified numerous loss-of-function alterations in cancer cells. While these alterations are difficult to target using direct interventions, they may be attacked with the help of the synthetic lethality (SL) approach. In this approach, inhibition of one gene causes lethality only when another gene is also completely or partially inactivated.
    [Show full text]
  • Combination of Photodynamic Therapy with Fenretinide and C6
    Wayne State University Wayne State University Theses 1-1-2015 Combination Of Photodynamic Therapy With Fenretinide And C6-Pyridinium Ceramide Enhances Killing Of Scc17b Human Head And Neck Squamous Cell Carcinoma Cells Via The eD Novo Sphingolipid Biosynthesis And Mitochondrial Apoptosis Nithin Bhargava Boppana Wayne State University, Follow this and additional works at: https://digitalcommons.wayne.edu/oa_theses Part of the Medicinal Chemistry and Pharmaceutics Commons Recommended Citation Boppana, Nithin Bhargava, "Combination Of Photodynamic Therapy With Fenretinide And C6-Pyridinium Ceramide Enhances Killing Of Scc17b Human Head And Neck Squamous Cell Carcinoma Cells Via The eD Novo Sphingolipid Biosynthesis And Mitochondrial Apoptosis" (2015). Wayne State University Theses. 431. https://digitalcommons.wayne.edu/oa_theses/431 This Open Access Thesis is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Theses by an authorized administrator of DigitalCommons@WayneState. COMBINATION OF PHOTODYNAMIC THERAPY WITH FENRETINIDE AND C6-PYRIDINIUM CERAMIDE ENHANCES KILLING OF SCC17B HUMAN HEAD AND NECK SQUAMOUS CELL CARCINOMA CELLS VIA THE DE NOVO SPHINGOLIPID BIOSYNTHESIS AND MITOCHONDRIAL APOPTOSIS by NITHIN BHARGAVA BOPPANA THESIS Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE 2015 MAJOR: PHARMACEUTICAL SCIENCES Approved By: ________________________________ Advisor Date © COPYRIGHT BY NITHIN BHARGAVA BOPPANA 2015 All Rights Reserved DEDICATION Dedicated to my mom Rekha Vasireddy for always believing in me and helping me in becoming the person who I am today. ii ACKNOWLEDGEMENTS I am grateful to my advisor, Dr. Duska Separovic for her invaluable mentorship throughout the project.
    [Show full text]
  • Structure of the Dock2âˆ'elmo1 Complex Provides Insights Into
    ARTICLE https://doi.org/10.1038/s41467-020-17271-9 OPEN Structure of the DOCK2−ELMO1 complex provides insights into regulation of the auto-inhibited state Leifu Chang1,7, Jing Yang1, Chang Hwa Jo 2, Andreas Boland 1,8, Ziguo Zhang 1, Stephen H. McLaughlin 1, Afnan Abu-Thuraia 3, Ryan C. Killoran2, Matthew J. Smith 2,4,9, Jean-Francois Côté 3,5,6,9 & ✉ David Barford 1 DOCK (dedicator of cytokinesis) proteins are multidomain guanine nucleotide exchange 1234567890():,; factors (GEFs) for RHO GTPases that regulate intracellular actin dynamics. DOCK proteins share catalytic (DOCKDHR2) and membrane-associated (DOCKDHR1) domains. The structurally-related DOCK1 and DOCK2 GEFs are specific for RAC, and require ELMO (engulfment and cell motility) proteins for function. The N-terminal RAS-binding domain (RBD) of ELMO (ELMORBD) interacts with RHOG to modulate DOCK1/2 activity. Here, we determine the cryo-EM structures of DOCK2−ELMO1 alone, and as a ternary complex with RAC1, together with the crystal structure of a RHOG−ELMO2RBD complex. The binary DOCK2−ELMO1 complex adopts a closed, auto-inhibited conformation. Relief of auto- inhibition to an active, open state, due to a conformational change of the ELMO1 subunit, exposes binding sites for RAC1 on DOCK2DHR2, and RHOG and BAI GPCRs on ELMO1. Our structure explains how up-stream effectors, including DOCK2 and ELMO1 phosphorylation, destabilise the auto-inhibited state to promote an active GEF. 1 MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK. 2 Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec H3T 1J4, Canada. 3 Montreal Institute of Clinical Research (IRCM), Montréal, QC H2W 1R7, Canada.
    [Show full text]
  • Atlas Antibodies in Breast Cancer Research Table of Contents
    ATLAS ANTIBODIES IN BREAST CANCER RESEARCH TABLE OF CONTENTS The Human Protein Atlas, Triple A Polyclonals and PrecisA Monoclonals (4-5) Clinical markers (6) Antibodies used in breast cancer research (7-13) Antibodies against MammaPrint and other gene expression test proteins (14-16) Antibodies identified in the Human Protein Atlas (17-14) Finding cancer biomarkers, as exemplified by RBM3, granulin and anillin (19-22) Co-Development program (23) Contact (24) Page 2 (24) Page 3 (24) The Human Protein Atlas: a map of the Human Proteome The Human Protein Atlas (HPA) is a The Human Protein Atlas consortium cell types. All the IHC images for Swedish-based program initiated in is mainly funded by the Knut and Alice the normal tissue have undergone 2003 with the aim to map all the human Wallenberg Foundation. pathology-based annotation of proteins in cells, tissues and organs expression levels. using integration of various omics The Human Protein Atlas consists of technologies, including antibody- six separate parts, each focusing on References based imaging, mass spectrometry- a particular aspect of the genome- 1. Sjöstedt E, et al. (2020) An atlas of the based proteomics, transcriptomics wide analysis of the human proteins: protein-coding genes in the human, pig, and and systems biology. mouse brain. Science 367(6482) 2. Thul PJ, et al. (2017) A subcellular map of • The Tissue Atlas shows the the human proteome. Science. 356(6340): All the data in the knowledge resource distribution of proteins across all eaal3321 is open access to allow scientists both major tissues and organs in the 3.
    [Show full text]
  • Pi3kp110-, Src-, FAK-Dependent and DOCK2-Independent Migration and Invasion of CXCL13-Stimulated Prostate Cancer Cells
    El Haibi et al. Molecular Cancer 2010, 9:85 http://www.molecular-cancer.com/content/9/1/85 RESEARCH Open Access PI3Kp110-,Research Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells Christelle P El Haibi1, Praveen K Sharma2, Rajesh Singh3, Paul R Johnson4, Jill Suttles2, Shailesh Singh3 and James W Lillard Jr*3 Abstract Background: Most prostate cancer (PCa)-related deaths are due to metastasis, which is mediated in part by chemokine receptor and corresponding ligand interaction. We have previously shown that PCa tissue and cell lines express high levels of the chemokine receptor CXCR5, than compared to their normal counterparts, and interaction of CXCR5 with its specific ligand (CXCL13) promoted PCa cell invasion, migration, and differential matrix metalloproteinase (MMP) expression. This study dissects some of the molecular mechanisms following CXCL13-CXCR5 interaction that mediate PCa cell migration and invasion. Results: Using Western blot analysis, kinase-specific cell-based ELISAs, and migration and invasion assays, we show that PCa cell lines differentially express phosphoinositide-3 kinase (PI3K) catalytic subunit isoforms and dedicator of cytokinesis 2 (DOCK2). Specifically, we show that PC3 and normal prostatic epithelial (RWPE-1), but not LNCaP cell lines expressed DOCK2, while RWPE, PC3, and LNCaP cell lines expressed PI3K-p110α and -p110β. Moreover, PC3 selectively expressed PI3K-p110γ, but LNCaP and RWPE cell lines expressed PI3Kp110δ. CXCL13 caused CXCR5-dependent activation of the PI3Kp85α in LNCaP cells, and p85α as well as -p101 in PC3 cells. CXCL13-CXCR5 interaction regulated LNCaP and PC3 cell migration and invasion through extracellular signal-regulated kinase 1/2 (ERK1/2) activation that was primarily dependent on the PI3Kp110 isoform(s), Src, and focal adhesion kinase (FAK), but not DOCK2.
    [Show full text]
  • The Kinase Defective EPHB6 Receptor Tyrosine Kinase Activates MAP Kinase Signaling in Lung Adenocarcinoma
    175-179.qxd 29/5/2009 01:21 ÌÌ ™ÂÏ›‰·175 INTERNATIONAL JOURNAL OF ONCOLOGY 35: 175-179, 2009 175 The kinase defective EPHB6 receptor tyrosine kinase activates MAP kinase signaling in lung adenocarcinoma JUN YU1,2, ETMAR BULK1, PING JI1, ANTJE HASCHER1, STEFFEN KOSCHMIEDER1, WOLFGANG E. BERDEL1 and CARSTEN MÜLLER-TIDOW1 1Department of Medicine, Hematology and Oncology, University of Münster, Münster, Germany; 2Department of Preclinical Experiment Center, Fourth Military Medical University, Xi'an, P.R. China Received January 28, 2009; Accepted March 13, 2009 DOI: 10.3892/ijo_00000326 Abstract. Decreased expression levels of EPHB6, a member Elk-1 (8,9). ERK1/2 are negatively regulated by a family of of the receptor tyrosine kinases (RTKs), are associated with dual-specificity (Thr/Tyr) MAPK phosphatases, known as an increased risk of metastasis development in early stage DUSPs or MKPs, and pharmacologically by MEK inhibitors non-small cell lung cancer (NSCLC). However, the signaling such as U0126 and PD98059 (10). properties of the kinase-defective EPHB6 receptor are not EPH receptors form the largest known subfamily of well-understood. Here, we show that expression of EPHB6 receptor tyrosine kinases, and to date, the EPH subfamily in A549 lung adenocarinoma cells led to phosphorylation of contains 16 members in vertebrates (11,12). The EPH receptors the MAP kinase ERK. Conversely, siRNA based knockdown interact with a family of ligands located on the surfaces of of EPHB6 reversed ERK phosphorylation. Intriguingly, adjacent cells, named Ephrins including Ephrin-As and EPHB6-induced phosphorylation of ERK was uncoupled Ephrin-Bs subgroups. The EPH receptors are also grouped by activation of the Elk-1 transcriptional factor.
    [Show full text]
  • Β-Catenin Confers Resistance to PI3K and AKT Inhibitors and Subverts Foxo3a to Promote Metastasis in Colon Cancer
    β-catenin Confers Resistance to PI3K and AKT inhibitors and Subverts FOXO3a to Promote Metastasis in Colon Cancer Stephan P. Tenbaum1§, Paloma Ordóñez-Morán2§#, Isabel Puig1§, Irene Chicote1, Oriol Arqués1, Stefania Landolfi3, Yolanda Fernández4, José Raúl Herance5, Juan D. Gispert5, Leire Mendizabal6, Susana Aguilar7, Santiago Ramón y Cajal3, Simó Schwartz Jr4, Ana Vivancos6, Eloy Espín8, Santiago Rojas5, José Baselga9, Josep Tabernero10, Alberto Muñoz2, Héctor G. Palmer1* 1 Vall d’Hebrón Institut d´Oncología (VHIO). Stem Cells and Cancer Laboratory. Barcelona, Spain. 2 Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain. 3 Department of Pathology, Hospital Universitari Vall d'Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain. 4 Group of Drug Delivery and Targeting, CIBBIM-Nanomedicine and Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Hospital Universitari Vall d’Hebrón, Institut de Recerca Vall d’Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain. 5 Parc de Recerca Biomèdica de Barcelona (PRBB), Centre d´Imatge Molecular (CRC) Corporació Sanitària, Barcelona, Spain. 6 Vall d’Hebrón Institut d´Oncología (VHIO). Genomics Cancer Group. Barcelona, Spain. 7 Centre for Respiratory Research, Rayne Institute, University College London, London, United Kingdom, Hematopoietic Stem Cell Laboratory, London Research Institute, Cancer Research UK, London, United Kingdom. 8 General Surgery Service, Hospital Universitari Vall d'Hebrón, Barcelona, Spain. 9 Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, USA; Howard Hughes Medical Institute, Chevy Chase, USA. 10 Medical Oncology Department, Hospital Universitari Vall d'Hebrón, Barcelona, Spain. # Swiss Institute for Experimental Cancer Research, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
    [Show full text]
  • 3 Cleavage Products of Notch 2/Site and Myelopoiesis by Dysregulating
    ADAM10 Overexpression Shifts Lympho- and Myelopoiesis by Dysregulating Site 2/Site 3 Cleavage Products of Notch This information is current as David R. Gibb, Sheinei J. Saleem, Dae-Joong Kang, Mark of October 4, 2021. A. Subler and Daniel H. Conrad J Immunol 2011; 186:4244-4252; Prepublished online 2 March 2011; doi: 10.4049/jimmunol.1003318 http://www.jimmunol.org/content/186/7/4244 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2011/03/02/jimmunol.100331 Material 8.DC1 http://www.jimmunol.org/ References This article cites 45 articles, 16 of which you can access for free at: http://www.jimmunol.org/content/186/7/4244.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 4, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology ADAM10 Overexpression Shifts Lympho- and Myelopoiesis by Dysregulating Site 2/Site 3 Cleavage Products of Notch David R.
    [Show full text]
  • Circular RNA Hsa Circ 0005114‑Mir‑142‑3P/Mir‑590‑5P‑ Adenomatous
    ONCOLOGY LETTERS 21: 58, 2021 Circular RNA hsa_circ_0005114‑miR‑142‑3p/miR‑590‑5p‑ adenomatous polyposis coli protein axis as a potential target for treatment of glioma BO WEI1*, LE WANG2* and JINGWEI ZHAO1 1Department of Neurosurgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033; 2Department of Ophthalmology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130021, P.R. China Received September 12, 2019; Accepted October 22, 2020 DOI: 10.3892/ol.2020.12320 Abstract. Glioma is the most common type of brain tumor APC expression with a good overall survival rate. UALCAN and is associated with a high mortality rate. Despite recent analysis using TCGA data of glioblastoma multiforme and the advances in treatment options, the overall prognosis in patients GSE25632 and GSE103229 microarray datasets showed that with glioma remains poor. Studies have suggested that circular hsa‑miR‑142‑3p/hsa‑miR‑590‑5p was upregulated and APC (circ)RNAs serve important roles in the development and was downregulated. Thus, hsa‑miR‑142‑3p/hsa‑miR‑590‑5p‑ progression of glioma and may have potential as therapeutic APC‑related circ/ceRNA axes may be important in glioma, targets. However, the expression profiles of circRNAs and their and hsa_circ_0005114 interacted with both of these miRNAs. functions in glioma have rarely been studied. The present study Functional analysis showed that hsa_circ_0005114 was aimed to screen differentially expressed circRNAs (DECs) involved in insulin secretion, while APC was associated with between glioma and normal brain tissues using sequencing the Wnt signaling pathway. In conclusion, hsa_circ_0005114‑ data collected from the Gene Expression Omnibus database miR‑142‑3p/miR‑590‑5p‑APC ceRNA axes may be potential (GSE86202 and GSE92322 datasets) and explain their mecha‑ targets for the treatment of glioma.
    [Show full text]
  • ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease
    International Journal of Molecular Sciences Review ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease Francesca Tosetti 1,* , Massimo Alessio 2, Alessandro Poggi 1,† and Maria Raffaella Zocchi 3,† 1 Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico S. Martino Largo R. Benzi 10, 16132 Genoa, Italy; [email protected] 2 Proteome Biochemistry, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] 3 Division of Immunology, Transplants and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work as last author. Abstract: Enzymes, once considered static molecular machines acting in defined spatial patterns and sites of action, move to different intra- and extracellular locations, changing their function. This topological regulation revealed a close cross-talk between proteases and signaling events involving post-translational modifications, membrane tyrosine kinase receptors and G-protein coupled recep- tors, motor proteins shuttling cargos in intracellular vesicles, and small-molecule messengers. Here, we highlight recent advances in our knowledge of regulation and function of A Disintegrin And Metalloproteinase (ADAM) endopeptidases at specific subcellular sites, or in multimolecular com- plexes, with a special focus on ADAM10, and tumor necrosis factor-α convertase (TACE/ADAM17), since these two enzymes belong to the same family, share selected substrates and bioactivity. We will discuss some examples of ADAM10 activity modulated by changing partners and subcellular compartmentalization, with the underlying hypothesis that restraining protease activity by spatial Citation: Tosetti, F.; Alessio, M.; segregation is a complex and powerful regulatory tool.
    [Show full text]
  • Cell-Autonomous FLT3L Shedding Via ADAM10 Mediates Conventional Dendritic Cell Development in Mouse Spleen
    Cell-autonomous FLT3L shedding via ADAM10 mediates conventional dendritic cell development in mouse spleen Kohei Fujitaa,b,1, Svetoslav Chakarovc,1, Tetsuro Kobayashid, Keiko Sakamotod, Benjamin Voisind, Kaibo Duanc, Taneaki Nakagawaa, Keisuke Horiuchie, Masayuki Amagaib, Florent Ginhouxc, and Keisuke Nagaod,2 aDepartment of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan; bDepartment of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan; cSingapore Immunology Network, Agency for Science, Technology and Research, Biopolis, 138648 Singapore; dDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892; and eDepartment of Orthopedic Surgery, National Defense Medical College, Tokorozawa 359-8513, Japan Edited by Kenneth M. Murphy, Washington University School of Medicine, St. Louis, MO, and approved June 10, 2019 (received for review November 4, 2018) Conventional dendritic cells (cDCs) derive from bone marrow (BM) intocDC1sorcDC2stakesplaceintheBM(3),andthese precursors that undergo cascades of developmental programs to pre-cDC1s and pre-cDC2s ultimately differentiate into cDC1s terminally differentiate in peripheral tissues. Pre-cDC1s and pre- and cDC2s after migrating to nonlymphoid and lymphoid tissues. + + cDC2s commit in the BM to each differentiate into CD8α /CD103 cDCs are short-lived, and their homeostatic maintenance relies + cDC1s and CD11b cDC2s, respectively. Although both cDCs rely on on constant replenishment from the BM precursors (5). The cy- the cytokine FLT3L during development, mechanisms that ensure tokine Fms-related tyrosine kinase 3 ligand (FLT3L) (12), by cDC accessibility to FLT3L have yet to be elucidated. Here, we gen- signaling through its receptor FLT3 expressed on DC precursors, erated mice that lacked a disintegrin and metalloproteinase (ADAM) is essential during the development of DCs (7, 13).
    [Show full text]
  • Multi-Modal Meta-Analysis of 1494 Hepatocellular Carcinoma Samples Reveals
    Author Manuscript Published OnlineFirst on September 21, 2018; DOI: 10.1158/1078-0432.CCR-18-0088 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Multi-modal meta-analysis of 1494 hepatocellular carcinoma samples reveals significant impact of consensus driver genes on phenotypes Kumardeep Chaudhary1, Olivier B Poirion1, Liangqun Lu1,2, Sijia Huang1,2, Travers Ching1,2, Lana X Garmire1,2,3* 1Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA 2Molecular Biosciences and Bioengineering Graduate Program, University of Hawaii at Manoa, Honolulu, HI 96822, USA 3Current affiliation: Department of Computational Medicine and Bioinformatics, Building 520, 1600 Huron Parkway, Ann Arbor, MI 48109 Short Title: Impact of consensus driver genes in hepatocellular carcinoma * To whom correspondence should be addressed. Lana X. Garmire, Department of Computational Medicine and Bioinformatics Medical School, University of Michigan Building 520, 1600 Huron Parkway Ann Arbor-48109, MI, USA, Phone: +1-(734) 615-5510 Current email address: [email protected] Grant Support: This research was supported by grants K01ES025434 awarded by NIEHS through funds provided by the trans-NIH Big Data to Knowledge (BD2K) initiative (http://datascience.nih.gov/bd2k), P20 COBRE GM103457 awarded by NIH/NIGMS, NICHD R01 HD084633 and NLM R01LM012373 and Hawaii Community Foundation Medical Research Grant 14ADVC-64566 to Lana X Garmire. 1 Downloaded from clincancerres.aacrjournals.org on October 1, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 21, 2018; DOI: 10.1158/1078-0432.CCR-18-0088 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]